Participating Faculty

December 15, 2006
Supplements and Featured Publications, Emerging Antithrombotic Therapies: New Developments in Acute Care Medicine, Volume 12, Issue 16 Suppl

The American Journal of Managed Care

This supplement to provides information on the medicaland economic burden associated with acute coronary syndromes (ACS) and emergent treatmentof ACS. Efficacy, safety, and cost-effectiveness of current and emerging antithrombotic therapiesare discussed.

Faculty

Charles L. Campbell, MD

Director of Coronary Care Unit

Assistant Professor of Medicine

Division of Cardiovascular Medicine

University of Kentucky

Lexington, Kentucky

Edith A. Nutescu, PharmD

Clinical Associate Professor

Department of Pharmacy Practice

University of Illinois at Chicago—College of Pharmacy

Chicago, Illinois

Alexander G. G. Turpie, MD

Professor of Medicine

McMaster University

Internist

Hamilton Health Sciences

General Hospital

Hamilton, Ontario, Canada

Disclosure Statement

The American Journal of Managed Care

It is the policy of to have all faculty who participatein programs sponsored by pharmaceutical organizations disclose any real or apparent conflicts of interest.

These participants report relationships with the following pharmaceutical companies:

  • Edith A. Nutescu, PharmDSpeakers' bureau:GlaxoSmithKlineSanofi-Aventis
  • Alexander G. G. Turpie, MDConsultant:BayerGlaxoSmithKlinePfizer IncSanofi-AventisSpeakers' bureau:Pfizer IncSanofi-Aventis

The following participant has declared no financial affilitations with corporate organizations:

  • Charles L. Campbell, MD

Thomas May and Kenneth Lane contributed to the writing of the articles in this supplement, as notedin the footnotes.

The American Journal of Managed Care

Signed disclosures are on file at the office of , Princeton,New Jersey.

GOAL

To provide participants with information about medical and economic costs of treatment of acute coronary syndromes(ACS), and to present data from recent clinical trials on emerging antithrombotic therapies.

TARGET AUDIENCE

This activity is intended for physicians, medical directors, pharmacists, and pharmacy directors.

EDUCATIONAL OBJECTIVES

After completing this continuing education activity, the participant should be able to:

  • Describe the medical and economic cost burden of ACS and related thrombotic illnesses.
  • Discuss the older and emerging acute care therapies for ACS.
  • Compare the safety and cost-effectiveness of the newer ACS pharmacotherapies,the pentasaccharide factor Xa inhibitors.
  • Understand the formulary issues involved in ACS treatment.

CONTINUING MEDICAL EDUCATION ACCREDITATION

AMA PRA Category 1 CME

credit(s)

The University of Cincinnati College of Medicine designates this activity for a maximum of 2 ™. Each physician should claim only those hours that he/she actually spends in the educational activity.

The University of Cincinnati College of Medicine is accredited by the Accreditation Council for Continuing MedicalEducation (ACCME) to sponsor medical education for physicians. Release Date: December 1, 2006. Expiration Date:December 1, 2007.

CONTINUING PHARMACY EDUCATION ACCREDITATION

Pharmacy Times

/Ascend Media is accredited by the Accreditation Council for Pharmacy Education (ACPE) asa provider of continuing pharmacy education. This program is approved for 2 contact hours (0.2 CEUs) underthe ACPE universal program number of 290-999-06-011-H01. Release Date: December 1, 2006. ExpirationDate: December 1, 2007.

FUNDING

This program is supported by an unrestricted educational grant from GlaxoSmithKline.

•••

The contents of this supplement may include information regarding the use of products that may be inconsistentoutside the approved labeling for these products in the United States. Physicians should note that the use of theseproducts outside current approved labeling is considered experimental and are advised to consult prescribing informationfor these products.

Fondaparinux sodium is currently under review by the FDA for use in acute coronary syndromes (ACS);however, it is not yet approved for that indication.